-transparent.png){kind=logo}
Alpha-2-interferon (IFN) has demonstrable activity in advanced, relapsing, or refractory multiple myeloma. Because of the in vitro synergism between the IFNs and cytotoxic agents, we conducted a trial of 30 previously untreated patients with multiple myeloma utilizing various doses of alpha-2-IFN in combination with standard oral doses of melphalan and prednisone. The combination was well-tolerated without unusual or unexpected toxic effects. The limiting toxicity included dose-related myelosuppression, and alpha-2-IFN induced flu-like symptoms and fatigue. Response was seen in at least as many patients as would be expected with melphalan and prednisone alone. The maximal tolerated dose for a phase II-III trial was 5.0 X 10(6) IU/m2 of alpha-2-IFN in combination with standard doses of melphalan and prednisone. Future trials should utilize this dose of alpha-2-IFN with dose de-escalation according to tolerance.
M R Cooper, and
A Fefer, and
J Thompson, and
D C Case, and
R Kempf, and
R Sacher, and
J Neefe, and
J Bickers, and
J H Scarffe, and
R Spiegel
November 1990,
British journal of haematology,
M R Cooper, and
A Fefer, and
J Thompson, and
D C Case, and
R Kempf, and
R Sacher, and
J Neefe, and
J Bickers, and
J H Scarffe, and
R Spiegel
February 2013,
Clinical lymphoma, myeloma & leukemia,
M R Cooper, and
A Fefer, and
J Thompson, and
D C Case, and
R Kempf, and
R Sacher, and
J Neefe, and
J Bickers, and
J H Scarffe, and
R Spiegel
July 2013,
Cancer science,
M R Cooper, and
A Fefer, and
J Thompson, and
D C Case, and
R Kempf, and
R Sacher, and
J Neefe, and
J Bickers, and
J H Scarffe, and
R Spiegel
January 1991,
European journal of cancer (Oxford, England : 1990),
M R Cooper, and
A Fefer, and
J Thompson, and
D C Case, and
R Kempf, and
R Sacher, and
J Neefe, and
J Bickers, and
J H Scarffe, and
R Spiegel
July 1984,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M R Cooper, and
A Fefer, and
J Thompson, and
D C Case, and
R Kempf, and
R Sacher, and
J Neefe, and
J Bickers, and
J H Scarffe, and
R Spiegel
March 2016,
Blood,
M R Cooper, and
A Fefer, and
J Thompson, and
D C Case, and
R Kempf, and
R Sacher, and
J Neefe, and
J Bickers, and
J H Scarffe, and
R Spiegel
May 2010,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M R Cooper, and
A Fefer, and
J Thompson, and
D C Case, and
R Kempf, and
R Sacher, and
J Neefe, and
J Bickers, and
J H Scarffe, and
R Spiegel
February 2013,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
M R Cooper, and
A Fefer, and
J Thompson, and
D C Case, and
R Kempf, and
R Sacher, and
J Neefe, and
J Bickers, and
J H Scarffe, and
R Spiegel
July 2010,
Haematologica,
M R Cooper, and
A Fefer, and
J Thompson, and
D C Case, and
R Kempf, and
R Sacher, and
J Neefe, and
J Bickers, and
J H Scarffe, and
R Spiegel
October 2006,
Blood,
